Prognostic factors in patients with metastatic spinal cord compression secondary to lung cancer—A retrospective UK single-centre study

Journal article


Anna Vassiliou, Temidayo Osunronbi, Synthia Enyioma, Gerardo Rago, Afroditi Karathanasi, Aruni Ghose, Matin Sheriff, Christos Mikropoulos, Elisabet Sanchez, Michele Moschetta, Cyrus Chargari, Elie Rassy and Stergios Boussios 2023. Prognostic factors in patients with metastatic spinal cord compression secondary to lung cancer—A retrospective UK single-centre study. Cancers. 15 (18), p. 4432. https://doi.org/10.3390/cancers15184432
AuthorsAnna Vassiliou, Temidayo Osunronbi, Synthia Enyioma, Gerardo Rago, Afroditi Karathanasi, Aruni Ghose, Matin Sheriff, Christos Mikropoulos, Elisabet Sanchez, Michele Moschetta, Cyrus Chargari, Elie Rassy and Stergios Boussios
Abstract

Purpose: Metastatic spinal cord compression (MSCC) is a severe complication of cancer that can lead to irreversible neurological impairment, necessitating prompt recognition and intervention. This retrospective, single-centre study aimed to determine the prognostic factors and survival rates among patients presenting with MSCC secondary to lung cancer.

Methods and Materials: We identified 74 patients with epidural metastases-related spinal cord compression and a history of lung cancer through the electronic database of Medway Maritime Hospital in the United Kingdom (UK), spanning the period from April 2016 to September 2021. Among them, 39 were below 55 years old, while 35 were aged 55 years or older; 24 patients were diagnosed with small cell lung cancer (SCLC), and 50 patients had non-small cell lung cancer (NSCLC).

Results: The median overall survival (OS) was 5.5 months, with 52 out of 74 patients dying within 6 months of diagnosis with MSCC. For the entire cohort, the statistically significant variables on multi-variate analysis were cancer type (NSCLC had improved OS), the number of involved vertebrae (one to two vertebrae involvement had improved OS), and the time taken to develop motor deficits (≤10 days to develop motor deficits had worsened OS). For the NSCLC cohort, the statistically significant variables on multivariate analysis were molecular alterations (patients with epidermal growth factor receptor (EGFR) mutation), pre-treatment ambulatory status, Eastern Cooperative Oncology Group (ECOG) performance status, and the time taken to develop motor deficits.

Conclusions: Within the entire cohort, patients diagnosed with NSCLC and spinal metastases affecting one to two vertebrae exhibited enhanced OS. Within the NSCLC subgroup, those with EGFR mutations who were ambulatory and possessed an ECOG performance status of 1–2 demonstrated improved OS. In both the entire cohort and the NSCLC subgroup, the development of motor deficits within a period of ≤10 days was associated with poor OS.

KeywordsMetastatic spinal cord compression; Lung cancer; Survivor; Prognostic factors
Year2023
JournalCancers
Journal citation15 (18), p. 4432
PublisherMDPI
ISSN2072-6694
Digital Object Identifier (DOI)https://doi.org/10.3390/cancers15184432
Official URLhttps://www.mdpi.com/2072-6694/15/18/4432
Publication dates
Online06 Sep 2023
Publication process dates
Accepted04 Sep 2023
Deposited07 Dec 2023
Publisher's version
License
File Access Level
Open
Output statusPublished
Permalink -

https://repository.canterbury.ac.uk/item/96887/prognostic-factors-in-patients-with-metastatic-spinal-cord-compression-secondary-to-lung-cancer-a-retrospective-uk-single-centre-study

Download files


Publisher's version
cancers-15-04432.pdf
License: CC BY 4.0
File access level: Open

  • 28
    total views
  • 8
    total downloads
  • 0
    views this month
  • 0
    downloads this month

Export as

Related outputs

Immunotherapy combined with standard therapies in head and neck squamous cell carcinoma - a meta-analysis
Eden, Daisy, Ghose, Aruni, Moschetta, Michele, Pérez-Fidalgo, José Alejandro, Rassy, Elie and Boussios, Stergios 2024. Immunotherapy combined with standard therapies in head and neck squamous cell carcinoma - a meta-analysis. Anticancer Research. 44 (3), pp. 861-878. https://doi.org/10.21873/anticanres.16880
Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4
Ghose, A., McCann, Lucy, Makker, S., Mukherjee, Uma, Gullapalli, Sri Vidya Niharika, Erekkath, Jayaraj, Shih, Stephanie, Mahajan, Ishika, Sanchez, Elisabet, Uccello, Mario, Moschetta, Michele, Adeleke, S. and Boussios, Stergios 2024. Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4. Therapeutic Advances in Medical Oncology. 16, p. 1758835924123225. https://doi.org/10.1177/17588359241233225
A rare case of metaplastic breast carcinoma from India: Towards precision oncology (Case Report)
Soirindhri Banerjee, Ishika Mahajan, Aruni Ghose, Stergios Boussios and Shivam Chakraborty 2024. A rare case of metaplastic breast carcinoma from India: Towards precision oncology (Case Report). Cancer Reports. https://doi.org/10.1002/cnr2.1997
Stage 3 N2 lung cancer: A multidisciplinary therapeutic conundrum
Lily Carter, Vedika Apte, Arushi Shukla, Aruni Ghose, Raj Mamidi, Alexandra Petohazi, Shania Makker, Soirindhri Banerjee, Stergios Boussios and Giuseppe L. Banna 2024. Stage 3 N2 lung cancer: A multidisciplinary therapeutic conundrum. Current Oncology Reports. 26, pp. 65-79.
Frontiers of molecular biology of cancer
Boussios, S., Sanchez, E. and Sheriff, M. 2023. Frontiers of molecular biology of cancer. International Journal of Molecular Sciences.
Frontiers of ovarian carcinosarcoma
Ismail, A., Choi, S. and Boussios, S. 2023. Frontiers of ovarian carcinosarcoma. Current Treatment Options in Oncology. https://doi.org/10.1007/s11864-023-01138-4
Astragaloside IV enhances the sensitivity of breast cancer stem cells to paclitaxel by inhibiting stemness
Ping Huang, Huachao Li, Liping Ren, Haimei Xie, Liushan Chen, Yuqi Liang, Yuyu Hu, Heloisa Sobreiro Selistre-de-Araujo, Stergios Boussios, Sachin R. Jhawar, Rutao Cui, Qian Zuo and Qianjun Chen 2023. Astragaloside IV enhances the sensitivity of breast cancer stem cells to paclitaxel by inhibiting stemness. Translational Cancer Research. 12 (12).
Hallmarks of the tumour microenvironment of gliomas and its interaction with emerging immunotherapy modalities
Christian A. Linares, Anjana Varghese, Aruni Ghose, Sayali D. Shinde, Sola Adeleke, Elisabet Sanchez, Matin Sheriff, Cyrus Chargari, Elie Rassy and Stergios Boussios 2023. Hallmarks of the tumour microenvironment of gliomas and its interaction with emerging immunotherapy modalities. International Journal of Molecular Sciences. 24 (17), p. 13215. https://doi.org/10.3390/ijms241713215
Exosomes in the diagnosis and treatment of renal cell cancer
Boussios, S., Devo, P., Goodall, Iain C A, Sirlantzis, Konstantinos, Ghose, A., Shinde, Sayali D, Papadopoulos, Vasileios, Sanchez, Elisabet, Rassy, E. and Ovsepian, Saak V 2023. Exosomes in the diagnosis and treatment of renal cell cancer. International Journal of Molecular Sciences. 24 (18), p. 14356. https://doi.org/10.3390/ijms241814356
Immunotherapy for advanced urothelial carcinoma (UC): rational and current evidence
Mario Uccello, Sola Adeleke, Michele Moschetta, Aruni Ghose and Stergios Boussios 2023. Immunotherapy for advanced urothelial carcinoma (UC): rational and current evidence. Annals of Palliative Medicine. https://doi.org/10.21037/apm-22-1350
Clinical challenges in the management of malignant ovarian germ cell tumours
Iqra Saani, Nitish Raj, Raja Sood, Shahbaz Ansari, Haider Abbas Mandviwala, Elisabet Sanchez and Stergios Boussios 2023. Clinical challenges in the management of malignant ovarian germ cell tumours. International Journal of Environmental Research and Public Health. 20 (12), p. 6089.
Impact of COVID-19 on cancer services and patients' outcomes: a retrospective single-center study
Baijaeek Sain, Arnab Gupta, Aruni Ghose, Sudip Halder, Samir Bhattacharya, Radha Raman Mondal, Subhamoy Paul, Chandrakanth Are and Stergios Boussios 2023. Impact of COVID-19 on cancer services and patients' outcomes: a retrospective single-center study. Annals of Translational Medicine. 11 (9). https://doi.org/10.21037/atm-22-5876
Advances in adoptive T-cell therapy for metastatic melanoma
Das, Aparimita, Ghose, Aruni, Naicker, Kevin, Sanchez, Elisabet, Chargari, Cyrus, Rassy, Elie and Boussios, S. 2023. Advances in adoptive T-cell therapy for metastatic melanoma. Current Research in Translational Medicine. 71 (3), p. 103404. https://doi.org/10.1016/j.retram.2023.103404
Prostate cancer - what about oligometastatic disease and stereotactic ablative radiotherapy? - a narrative review
Boussios, S., Saxby, H. and Mikropoulos, C. 2023. Prostate cancer - what about oligometastatic disease and stereotactic ablative radiotherapy? - a narrative review. Annals of Palliative Medicine. 12 (3). https://doi.org/10.21037/apm-22-828
HPV and cervical cancer: A review of epidemiology and screening uptake in the UK
Sunyoung Choi, Ayden Ismail, George Pappas-Gogos and Stergios Boussios 2023. HPV and cervical cancer: A review of epidemiology and screening uptake in the UK. Pathogens (Basel, Switzerland). 12 (2). https://doi.org/10.3390/pathogens12020298
Constrictive pericarditis–a cloak camouflaging lymphoma
Delanthabettu Venugopala, Nikhil Victor Dsouza, Vishak Acharya, Maneesh Rai, Chaithra Gowthuvalli Venkataramana and Stergios Boussios 2022. Constrictive pericarditis–a cloak camouflaging lymphoma. Hematology Reports. 15 (1), pp. 166-171. https://doi.org/10.3390/hematolrep15010017